Bayer US head says tariffs will not affect its 2026 forecasts

Bayer said it will not adjust its 2026 forecasts after U.S. tariffs on imported pharmaceuticals were announced last week, signaling management sees limited near-term earnings impact. The comment reduces immediate downside risk to the company's 2026 outlook, but investors should monitor any further tariff details or company sensitivity analyses that could change the assessment.

Analysis

Bayer said it will not adjust its 2026 forecasts after U.S. tariffs on imported pharmaceuticals were announced last week, signaling management sees limited near-term earnings impact. The comment reduces immediate downside risk to the company's 2026 outlook, but investors should monitor any further tariff details or company sensitivity analyses that could change the assessment.